Targeted antibody improves outcomes for patients with advanced lung cancer who have faced treatment resistance
Phase 3 HARMONi study evaluated ivonescimab plus chemotherapy for patients with EGFR-mutant lung cancer whose tumors stopped responding to treatment
This combination cut the risk of cancer progression nearly in half compared to chemotherapy alone
Patients on ivonescimab-chemotherapy treatment lived more than two months longer without their cancer worsening
HOUSTON, SEPTEMBER 4, 2026 — Patients with EGFR-mutant...
Psilocybin prevents chemotherapy-related nerve injury and associated symptoms in preclinical models
Peripheral neuropathy is a common side effect of chemotherapy treatment, resulting in symptoms that can include numbness, painful nerve injury...
Daraxonrasib demonstrates initial antitumor activity in RAS-mutant lung cancer
Daraxonrasib is a RAS inhibitor from Revolution Medicines that has been approved by the Food & Drug Administration for previously treated...